ulvovaginal candidiasis (VVC) is probably the most common form of vaginal infection, although bacterial vaginosis is believed to be more frequent. 1 It is estimated that 75% of all women will experience one episode of symptomatic VVC during their lifetime. 7, 8 Unfortunately, 40-50% of women will have at least one recurrence of VVC and at least 5% will have chronic or repeated episodes of VVC.
Perhaps this condition should be viewed as a disturbance in the vaginal ecosystem rather than a disease in view of the fact that Candida is part of the complex endogenous microflora of many individuals slowly being accumulated on a rising incidence of VVC due to non-albicans species such as C. (Torulopsis) glabrata, C. tropicalis, and C. krusei (Table 1) .9
This rising incidence has become even more of a concern in view of the availability of several antimycotic agents that no longer require a prescription (over-the-counter products). The easy accessibility of antimycotic intravaginal preparations has raised at least three major concerns: 1) The wanton or indiscriminate use of these agents may exert selective pressure for resistant strains; 2) the indiscriminate use of these agents may allow for replacement by other species such as C. glabrata, C. tropicalis, or C. krusei; and 3) the treatment may be misdirected if the individual has another or concomitant infection. Added to these concerns is the fact that the NEW TREATMENTS FOR VULVOVAGINAL CANDIDIASIS FARO Table 2 ). An algorithm for the management of acute VVC is given in Figure 1 .
Prior Fig. 1 ). Since these shortcourse regimens are as effective as the traditional longer therapeutic regimens, the former would probably achieve a better level of compliance. An algorithm for the management of chronic VVC is presented in Figure 2 . CONCLUSIONS VVC is a common condition inflicting a great deal of suffering on the infected patient, especially if she has chronic or recurrent infections. The approach to treating this condition has been to use intravaginal or oral antimycotics in an attempt to effect a cure. However, the objective of effecting a cure may be inappropriate. Since Candida is part of the endogenous microflora of the vaginal ecosystem, a more logical approach would be to reestablish a healthy or balanced vaginal ecosystem.
A healthy vaginal ecosystem could be achieved with either oral or vaginal short-course therapy. Single-dose therapy could be accomplished with oral fluconazole, 150 mg, or intravaginal tioconazole, 200 mg, or a 3-day regimen of terconazole ( Fig. 1) . These agents are as effective as longer therapeutic regimens, so the shorter therapeutic regimen should be associated with better compliance. In the European study of this international trial, the patients received 150 mg of fluconazole or placebo once a month for 4 months. 66 All patients were examined 6 months after the cessation of fluconazole prophylaxis. In this patient population, 53% of those receiving placebo experienced recurrent VVC compared with 39% of those receiving fluconazole (P--0.05). Over the 6-month follow-up period, no difference was noted with regard to recurrence of VVC between the two groups. 
